Список проголосовавших за комментарий " Gapping up/down: TIVO +14%, NTAP +5% and CSCO +2% after earnings, KATE +7% after earnings and announcing it will review strategic alt's; GNC -20%, MOH -17%, CAR -8%, MGM -5% after earnings<p><strong>Gapping up<br/> In reaction to strong earnings/guidance</strong>:</p><ul><li><strong>WINT</strong> +16.9%, <strong>TIVO</strong> +13.6%, <strong>CSLT</strong> +12.7%, <strong>SNPS</strong> +7.6%, <strong>NTES</strong> +7.3%, <strong>KATE</strong> +6.8% (also announce it is reviewing strategic alternatives) <strong>NTAP</strong> +5.3%</li><li><strong>QUIK</strong> +4.2%, <strong>CRY</strong> +4.1%, <strong>SRCL</strong> +4%, <strong>NGD</strong> +3.9%, <strong>TPX</strong> +3.9%, <strong>ALXN</strong> +3.4%, <strong>LBTYA</strong> +3.3%, <strong>CIR</strong> +3.3%, <strong>GNCA</strong> +2.4%, <strong>NMIH</strong> +2.1%, <strong>GG</strong> +2%, <strong>ABX</strong> +2%</li><li><strong>CHH</strong> +1.7%, <strong>CSCO</strong> +1.6%, <strong>SHPG</strong> +1.6%, <strong>EQIX</strong> +1.4%, <strong>AMAT</strong> +1.4%, <strong>SSNC</strong> +1.3%, <strong>PBFX</strong> +1.2%, <strong>GFI</strong> +1.2%, <strong>CVA</strong> +1%, <strong>TRP</strong> +1%</li></ul><p><strong>M&A news</strong>:</p><ul><li><strong>HGG</strong> +17.5% (HHGregg confirms plans to explore strategic alternatives)</li><li><strong>RAD</strong> +2.6% (Walgreens (WBA) is optimistic regarding FTC approval for RAD M&A deal due to divesture package, according to NY Post)</li><li><strong>BIDU</strong> +0.5% (acquired digital assistant startup Raven Tech, according to TechCrunch)</li></ul><p><strong>Other news</strong>:</p><ul><li><strong>XTLB</strong> +58.4% (continued strength), <strong>SCON</strong> +42.6% (receives a U.S. Patent enabled by STI's proprietary superconducting wire manufacturing method)</li><li><strong>MDGS</strong> +37.4% (announces tha tthe China FDA has approved the commencement of the first multi-center MUSE Clinical Study in China)</li><li><strong>CVRS</strong> +22.7% (Corindus Vascular Robotics announces a distribution agreement w/ a subsidiary of Mitsubishi (MSBHY); includes an initial order for 12 CorPath GRX Systems accompanied by an advance of $2 million toward the purchase price)</li><li><strong>RUBI</strong> +11% (SoundCloud selected Rubicon Project to automate its streaming audio and video ad inventory)</li><li><strong>BLDP</strong> +7.6% (receives 5-year, $25 mln deal Broad-Ocean Motor Co)</li><li><strong>PGNX</strong> +5.6% (to join S&P SmallCap 600), <strong>SFLY</strong> +3.1% (to join S&P SmallCap 600)</li><li><strong>VRX</strong> +2.6% (FDA approves Siliq to treat adults with moderate-to-severe plaque psoriasis)</li><li><strong>TTM</strong> +2.3% (Tata Motors and and Microsoft (MSFT) India confirm that cos will collaborate on connected cars)</li><li><strong>FOLD</strong> +2.1% (presents additional positive preliminary Phase 1/2 Data; demonstrates improving trends in majority of patients)</li><li><strong>FL</strong> +1.3% (increases quarterly dividend to $0.31/share from $0.28/share; approves a new 3-year $1.2 bln share repurchase program extending through January 2020, replacing the previous $1 bln program; approves $277 mln capital expenditure program for 2017)</li><li><strong>GSK</strong> +1% (in sympathy with SHPG earnings)</li><li><strong>ALGN</strong> +0.9% (announces it has prevailed in proceedings initiated by ClearCorrect Operating that challenged the validity of three of its U.S. patents)</li></ul><p><strong>Analyst comments</strong>:</p><ul><li><strong>MDCA</strong> +4.6% (upgraded to Buy from Hold at Jefferies)</li></ul><p><strong>Gapping down<br/> In reaction to disappointing earnings/guidance</strong>:</p><ul><li><strong>CFMS</strong> -38.6%, <strong>GNC</strong> -20.4%, <strong>BBW</strong> -17.6%, <strong>MOH</strong> -16.7%, <strong>CLD</strong> -14.8%, (Cloud Peak Energy replaces its throughput agreement with Westshore Terminals Limited Partnership)</li><li><strong>OMCL</strong> -10.8%, <strong>HAWK</strong> -9%, <strong>CAR</strong> -8.1%, <strong>AVP</strong> -6.1%, <strong>DF</strong> -6.1%, <strong>TRIP</strong> -5.8%, <strong>GDDY</strong> -5.8%, <strong>HOS</strong> -5%, <strong>MGM</strong> -4.7%, <strong>SPWR</strong> -4.6%, <strong>GEL</strong> -4%, <strong>CF</strong> -3.6%</li><li><strong>CAB</strong> -3.3%, <strong>MZOR</strong> -3.2%, <strong>LSCC</strong> -2.8%, <strong>MMLP</strong> -2.7%, (commences 2.6 mln common units offering), <strong>CNNX</strong> -2.7%, <strong>CYS</strong> -2.5%, <strong>AEM</strong> -2.4%, <strong>KHC</strong> -2.2%</li><li><strong>HIMX</strong> -1.9%, <strong>WM</strong> -1.8%, <strong>KGC</strong> -1.3%, <strong>CBS</strong> -1.1%, <strong>NCI</strong> -1.1%, <strong>QTWO</strong> -1%, <strong>NICE</strong> -1%, <strong>BCOR</strong> -1%, <strong>CSV</strong> -0.9%, <strong>DUK</strong> -0.9%</li></ul><p><strong>Other news</strong>:</p><ul><li><strong>ACUR</strong> -32.8% (to be delisted from the Nasdaq; will begin to trade on the OTCQB on February 23)</li><li><strong>EVOK</strong> -10.3% (intends to offer and sell shares of its common stock in a 'firm commitment' underwritten public offering)</li><li><strong>NGL</strong> -6% (upsizes offering by 800K units and prices 8.8 mln common units for gross proceeds of $198 mln)</li><li><strong>CRSP</strong> -5.7% (CRISPR Therapeutics to host call to provide update on the CRISPR/Cas9 U.S. patent interference proceedings and corresponding U.K. patents tomorrow February 16 at 11am ET)</li><li><strong>MMLP</strong> -2.7% (commences 2.6 mln common units offering)</li><li><strong>ATKR</strong> -2.4% (commences 8 mln common stock offering by selling stockholder CD&R Allied Holdings, L.P., an affiliate of Clayton, Dubilier & Rice)</li><li><strong>TRU</strong> -2.1% (prices secondary offering by certain of its stockholders of 19.85 mln shares of common stock)</li><li><strong>CNC</strong> -2% (MOH earnings/guidance sympathy)</li><li><strong>HTZ</strong> -1.4% (CAR sympathy)</li><li><strong>FRSH</strong> -0.9% (announces a strategic realignment of resources aimed at better supporting franchise-owners and field staff while reducing overall SG&A expenses; expects to achieve annual cost savings of $1.5 million)</li></ul><p><strong>Analyst comments</strong>:</p><ul><li><strong>OZM</strong> -3.1% (downgraded to Neutral from Overweight at JP Morgan)</li><li><strong>GRPN</strong> -2.4% (downgraded to Neutral from Outperform at Wedbush)</li><li><strong>WFC</strong> -0.6% (downgraded to Neutral from Outperform at Credit Suisse)</li></ul>"